ExCellThera
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2950 Chemin De Polytechnique, Montreal, ...Phone Number
(800) 307-6627Website
www.excellthera.comRevenue
$5.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About ExCellThera
ExCellThera is an advanced clinical-stage biotechnology company that specializes in cell expansion and engineering, focusing on providing innovative solutions for stem and immune cell therapies. Their proprietary Enhance Platform and UM171 Cell Therapy are designed to expand and rejuvenate hematopoietic stem cells for the treatment of blood cancers and other diseases. The company aims to deliver single-use curative therapies to patients suffering from hematological malignancies. ExCellThera serves healthcare providers and institutions looking for advanced therapeutic options in the field of cell therapy.Explore more
ExCellThera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ExCellThera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ExCellThera has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when ExCellThera launches new products
Earning: See what the market has to say on ExCellThera recently announced quarterly report
Click to see if ExCellThera had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ExCellThera is spiking on competitors!
ExCellThera, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at ExCellThera
Funding: Get notified immidiatlly once ExCellThera has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to ExCellThera
Compare insights from companies similar to ExCellThera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ExCellThera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ExCellThera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ExCellThera.
ExCellThera Tech Stack
A closer look at the technologies used by ExCellThera
See more technologies
Most Recent Scoops
Project
Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Project
Research & Development, Legal Affairs, Medical Research, Pharmaceuticals
Promotion
Executive Move
David Millette has been promoted from Chief Operating Officer & Chief Financial Officer to the role of Co-Chief Executive Officer & Chief Operating Officer.
Funding
Funding
ExCellThera News & Media
Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
- Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, recently received conditional marketing authorisation in Europe from the European Commission - Exclusive licensing and supply agreements have been granted to Medexus for the Canadian commercialization rights for Zemcelpro® (if...Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid,...Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromes Topline results from two Phase 2 studies to be presented on March 23, 2026 at the EBMT Annual Meeting in Madrid,...Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
The NUB designation for Zemcelpro® (dorocubicel) enables hospitals to immediately apply for temporary, supplementary reimbursement for its use. MONTREAL, Feb. 16, 2026 /PRNewswire/ - ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its...
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding ExCellThera
Sign Up For FreeTo access detailed company insights
ExCellThera is an advanced clinical-stage biotechnology company that specializes in cell expansion and engineering, focusing on providing innovative solutions for stem and immune cell therapies. Their proprietary Enhance Platform and UM171 Cell Therapy are designed to expand and rejuvenate hematopoietic stem cells for the treatment of blood cancers... Read More
